Cellectis (CLLS) Other Non-Current Liabilities (2015 - 2024)
Cellectis (CLLS) posted quarterly Other Non-Current Liabilities of $1.3 million for Q1 2026, up 16.24% year-over-year from $1.1 million in Q1 2025, and little changed quarter-over-quarter from $1.3 million in Q4 2025.
Analysis
Cellectis (CLLS) Other Non-Current Liabilities (2015 - 2024) Analysis & Trends
Cellectis' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 16.24% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 16.24% YoY), while the FY2025 annual figure was $1.3 million, up 19.19% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.3 million, roughly flat from $1.3 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $3.7 million in Q1 2022, with the low at $1.1 million in Q4 2024.
- The 5-year median for Other Non-Current Liabilities is $2.2 million (2024), against an average of $2.1 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities tumbled 49.32% in 2024, then advanced 19.19% in 2025.
- Cellectis' Other Non-Current Liabilities stood at $2.4 million in 2022, then slipped by 7.95% to $2.2 million in 2023, then sank by 49.32% to $1.1 million in 2024, then increased by 19.19% to $1.3 million in 2025, then fell by 0.38% to $1.3 million in 2026.
- Business Quant data shows CLLS's Other Non-Current Liabilities at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 138.58 Mn |
| Dec 31, 2023 | 135.15 Mn |
| Mar 31, 2023 | 13.21 Mn |
| Mar 31, 2022 | 73,000.00 |
| Dec 31, 2021 | 626,000.00 |
| Sep 30, 2021 | 787,000.00 |
| Jun 30, 2021 | 948,000.00 |
| Mar 31, 2021 | 1.11 Mn |
| Dec 31, 2015 | 23.34 Mn |